De medicamenteuze behandeling van chronisch obstructieve longziekte

Nederlands Tijdschrift voor Geneeskunde

Volumn 140, Issue 14, 1996, Pages 761-765

  Van Herwaarden, C L A ^a,b   Dekhuijzen, P N R ^a,b   Van Schayck, C P ^a,c   Van Weel, C ^a,c   Molema, J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Medisch Centrum Dekkerswald   (Netherlands)

^c Vakgroep Huisarts Social V ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; TERBUTALINE; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG EFFICACY; HUMAN; PATIENT COMPLIANCE; REVIEW;

ADRENERGIC BETA-AGONISTS; BRONCHODILATOR AGENTS; CLINICAL PROTOCOLS; DRUG THERAPY, COMBINATION; HUMANS; LUNG DISEASES, OBSTRUCTIVE; THEOPHYLLINE;

EID: 0029874808     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ad hoc-consensusgroep 'Diagnostiek van astma/chronisch obstructieve longziekte door de huisarts'. De diagnostiek van asthma bronchiale en chronisch obstructieve longziekte door de huisarts. Ned Tijdschr Geneeskd 1995;139:1966-71.
2. Waart MAC van der, Dekker FW, Nijhoff S, Thiadens HA, Weel C van, Helder M, et al. NHG-standaard CARA bij volwassenen: behandeling, Huisarts Wet 1992;35:437-43.
3. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir J 1995;8:1398-420.
4. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120.
5. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
6. 1. The Lung Health Study. JAMA 1994;272:1497-505.
7. Tashkin DP, Detels R, Simmons M, Liu H, Coulson AH, Sayre J, et al. The UCLA population studies of chronic obstructive respiratory disease. XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 1994;149:1209-17.
8. Nichol KL, Margolis KL, Wuorenma J, Sternberg T von. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331: 778-84.
9. Schayck CP van, Herwaarden CLA van, Folgering H, Akkermans R, Weel C van. Wanneer kan men volstaan met bronchusverwijders bij astma/chronisch obstructieve longziekte? Ned Tijdschr Geneeskd 1995;139:1580-3.
10. Marini JJ, Lakshminarayan S, Kradjan WA. Atropine and terbutaline aerosols in chronic bronchitis: efficacy and sites of action. Chest 1981;80:285-91.
11. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med 1991;91:28S-32S.
12. Schayck CP van, Folgering H, Harbers H, Maas KL, Weel C van. Acute medicamenteuze bronchusverwijding bij CARA: bij astma betere reactie op salbutamol en bij chronische bronchitis op ipratropium (bromide). Ned Tijdschr Geneeskd 1993;137:188-92.
13. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986;315:735-9.
14. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98:835-9.
15. Ghafouri MA, Patil KD, Kass I. Sputum changes associated with the use of ipratropium bromide. Chest 1984;86:387-93.
16. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411-9.
17. Dekhuijzen PNR, Heijden HFM van der, Herwaarden CLA van. The position of theophylline in the treatment of asthma and chronic obstructive pulmonary disease. Neth J Med 1995;46:213-6.
18. Wedzicha JA. Inhaled corticosteroids in COPD: awaiting controlled trials. Thorax 1993;48:305-7.
19. Auffarth B, Postma DS, Monchy JGR de, Mark TW van der, Boorsma M, Koëter GH. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough treshold in smokers with chronic obstructive lung disease. Thorax 1991;46: 372-7.
20. Watson A, Lim TK, Joyce H, Pride NB. Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction. Chest 1992;101:350-5.
21. Dompeling E, Schayck CP van, Grunsven PM van, Herwaarden CLA van, Akkermans R, Molema J, et al. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med 1993;118:770-8.
22. Kerstjens HAM, Brand PLP, Hughes MD, Robinson NJ. Postma DS, Sluiter HJ, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992;327:1413-9.
23. Dekhuijzen PNR, Boolsma GP, Herwaarden CLA van. Klinische effectiviteit en bijwerkingen van inhalatiecorticosteroïden bij de behandeling van astma. Ned Tijdschr Geneeskd 1994;138: 1408-13.
24. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991;114:216-23.
25. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis Suppl 1980;111:93-108.
26. Aylward M, Maddock J, Dewland P. Clinical evaluation of acetylcysleine in the treatment of patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control. Eur J Respir Dis Suppl 1980;111:81-9.
27. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983;64:405-15.
28. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988;1:351-5.
29. Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97:75-83.
30. Bergstrand H, Björnson A, Eklund A, Hernbrand R, Larsson K, Linden M, et al. Stimuli-induced superoxide radical generation in vitro by human alveolar macrophages from smokers: modulation by N-acetylcysteine treatment in vivo. J Free Radic Biol Med 1986;2: 119-27.
31. Herwaarden CLA van, Bast A, Dekhuijzen PNR. The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease. Neth J Med 1995;47:45-8.
32. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J 1994;7:94-101.
33. Borregaard N, Jensen HS, Bjerrum OW. Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of alpha i-proteinase inhibitor by N-acetyl cysteine, glutathione, and methionine. Agents Actions 1987;22:255-60.
34. Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985;132: 417-33.
35. Lundbäck B, Lindström M, Andersson S, Nyström L, Rosenhall L, Stjernberg N. Possible effect of acetylcystein on lung function. Eur Respir J Suppl 1992;15:289S.